View source for Sickle cell anemia - null regimens

<span id="BackToTop"></span>
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
[[#top|Back to Top]]
</div>
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the [[Sickle cell anemia|main sickle cell anemia page]] for regimens that include active treatment.

{{TOC limit|limit=3}}
=All lines of therapy=
==Observation==
<div class="toccolours" style="background-color:#eeeeee">
===Regimen===
{| class="wikitable sortable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|Dates of enrollment
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195437/ DeBaun et al. 2014 (SIT)]
|2004-2010
|style="background-color:#1a9851"|Phase 3 (C)
|[[Sickle_cell_anemia#RBC_transfusions|RBC transfusions]]
| style="background-color:#fc8d59" |Seems to have more cerebral infarcts (primary endpoint)
|-
|}
''No treatment.''
</div>

===References===
# '''SIT:''' DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, Meier ER, Howard TH, Majumdar S, Inusa BP, Telfer PT, Kirby-Allen M, McCavit TL, Kamdem A, Airewele G, Woods GM, Berman B, Panepinto JA, Fuh BR, Kwiatkowski JL, King AA, Fixler JM, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Dixon N, Gonzalez CE, Kalinyak KA, Quinn CT, Strouse JJ, Miller JP, Lehmann H, Kraut MA, Ball WS Jr, Hirtz D, Casella JF. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014 Aug 21;371(8):699-710. [https://doi.org/10.1056/NEJMoa1401731 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195437/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25140956/ PubMed] [https://clinicaltrials.gov/study/NCT00072761 NCT00072761]

==Placebo {{#subobject:9149f2|Regimen=1}}==
<div class="toccolours" style="background-color:#eeeeee">
===Regimen {{#subobject:71bcbf|Variant=1}}===
{| class="wikitable sortable" style="width: 100%; text-align:center;"
!style="width: 20%"|Study
!style="width: 20%"|Dates of enrollment
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
|-
|[https://doi.org/10.1182/blood.2022015797 Dampier et al. 2023 (RESET)]
|2015-06 to 2019-06
| style="background-color:#1a9851" |Phase 3 (C)
|[[#Rivipansel_monotherapy_999|Rivipansel]]
| style="background-color:#ffffbf" |Did not meet primary endpoint of TTRFD
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523370/ Heeney et al. 2022 (HESTIA3)]
|2018-09-26 to 2019-10-18
| style="background-color:#1a9851" |Phase 3 (C)
|[[#Ticagrelor_monotherapy_999|Ticagrelor]]
| style="background-color:#ffffbf" |Did not meet primary endpoint of reduced VOC rate
|-
|}
''No active treatment.''
</div>
===References===
# '''MSH:''' Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995 May 18;332(20):1317-22. [https://doi.org/10.1056/NEJM199505183322001 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/7715639/ PubMed]
## '''Update:''' Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003 Apr 2;289(13):1645-51. Erratum in: JAMA. 2003 Aug 13;290(6):756. [http://jama.jamanetwork.com/article.aspx?articleid=196300 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12672732/ PubMed]
## '''HRQoL analysis:''' Ballas SK, Barton FB, Waclawiw MA, Swerdlow P, Eckman JR, Pegelow CH, Koshy M, Barton BA, Bonds DR. Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes. 2006 Aug 31;4:59. [http://hqlo.biomedcentral.com/articles/10.1186/1477-7525-4-59 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1569824/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/16942629/ PubMed]
#'''BABY HUG:''' Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; BABY HUG investigators. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011 May 14;377(9778):1663-72. [https://doi.org/10.1016/s0140-6736(11)60355-3 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3133619/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21571150/ PubMed] [https://clinicaltrials.gov/study/NCT00006400 NCT00006400]
# '''SUSTAIN:''' Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017 Feb 2;376(5):429-439. Epub 2016 Dec 3. [https://doi.org/10.1056/NEJMoa1611770 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481200/ link to PMC article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/27959701/ PubMed] [https://clinicaltrials.gov/study/NCT01895361 NCT01895361]
# '''GLUSCC09-01:''' Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP; Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med. 2018 Jul 19;379(3):226-235. [https://doi.org/10.1056/NEJMoa1715971 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/30021096/ PubMed] [https://clinicaltrials.gov/study/NCT01179217 NCT01179217]
# '''HOPE:''' Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, Diuguid DL, Telfer P, Tsitsikas DA, Elghandour A, Gordeuk VR, Kanter J, Abboud MR, Lehrer-Graiwer J, Tonda M, Intondi A, Tong B, Howard J; HOPE Trial Investigators. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019 Aug 8;381(6):509-519. Epub 2019 Jun 14. [https://doi.org/10.1056/nejmoa1903212 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/31199090/ PubMed] [https://clinicaltrials.gov/study/NCT03036813 NCT03036813]
## '''Update:''' Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2021 May;8(5):e323-e333. Epub 2021 Apr 7. [https://doi.org/10.1016/s2352-3026(21)00059-4 link to original article] [https://pubmed.ncbi.nlm.nih.gov/33838113/ PubMed]
#'''HESTIA3:''' Heeney MM, Abboud MR, Githanga J, Inusa BPD, Kanter J, Michelson AD, Nduba V, Musiime V, Apte M, Inati A, Taksande AM, Andersson M, Åstrand M, Maklad N, Niazi M, Himmelmann A, Berggren AR. Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study. Blood. 2022 Sep 29;140(13):1470-1481. [https://doi.org/10.1182/blood.2021014095 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523370/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35849650/ PubMed] [https://clinicaltrials.gov/study/NCT03615924 NCT03615924]
#'''RESET:''' Dampier CD, Telen MJ, Wun T, Brown RC, Desai P, El Rassi F, Fuh B, Kanter J, Pastore Y, Rothman J, Taylor JG, Readett D, Sivamurthy KM, Tammara B, Tseng LJ, Lozier JN, Thackray H, Magnani JL, Hassell KL. A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis. Blood. 2023 Jan 12;141(2):168-179. [https://doi.org/10.1182/blood.2022015797 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35981565/ PubMed] [https://clinicaltrials.gov/study/NCT02187003 NCT02187003]

[[Category:Sickle cell anemia regimens]]
[[Category:Disease-specific pages]]
[[Category:Hemolytic process]]
[[Category:Inherited hemoglobinopathies]]
[[Category:Null regimens]]